Avista Capital Partners’ Investment in eMolecules

Ropes & Gray represented Avista Capital Partners, while Paul Hastings LLP represented eMolecules in the transaction.

Avista Capital Partners signed its agreement to invest in eMolecules, a novel and fast-growing e-procurement platform for high-value chemicals and bioreagents used by the leading pharmaceutical companies in drug discovery. Financial terms of the transaction were not disclosed.

Founded in 2005, Avista Capital is a leading New York-based private equity firm with over $6 billion invested in more than 35 growth-oriented healthcare businesses globally. 

Robert W. Baird & Co. served as exclusive financial advisor to eMolecules.

The Ropes & Gray team that represented Avista was led by private equity partner Bob Rivollierand (Picture) private equity associate David Sandyk (both of New York), and included health care partner Adrianne Ortega (Boston), IP transactions partner Violetta Kokolus (New York), employment, executive compensation & benefits partners Danna Kivell (New York) and Megan Bisk (Boston), tax partner Benjamin Rogers (San Francisco), litigation & enforcement partner Ryan Rohlfsen (Chicago), and real estate partner Peter Alpert (Boston).

Involved fees earner: Peter Alpert – Ropes & Gray; Megan Bisk – Ropes & Gray; Danna Kivell – Ropes & Gray; Violetta Kokolus – Ropes & Gray; Adrianne Ortega – Ropes & Gray; Bob Rivollier – Ropes & Gray; Benjamin Rogers – Ropes & Gray; Ryan Rohlfsen – Ropes & Gray; David Sandyk – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: Avista Capital Partners;

Author: Martina Bellini